Fasudil

RHO/ROCK pathway inhibitor; Inhibits ROCK2

Fasudil

RHO/ROCK pathway inhibitor; Inhibits ROCK2

From: 141 USD
Catalog #
(Select a product)
RHO/ROCK pathway inhibitor; Inhibits ROCK2
Add to Wish List

Overview

Fasudil (also known as HA-1077) is a potent inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2; IC₅₀ = 1.9 µM). Additionally, it inhibits protein kinase C-related kinase 2 (PRK2), mitogen- and stress-activated protein kinase (MSK1), and mitogen-activated protein kinase-activated protein kinase 1b (MAPKAP-K1b) with IC₅₀ values of 4, 5, and 15 µM, respectively (Davies et al.). This product is supplied as the dihydrochloride salt of the molecule.

DIFFERENTIATION
· Suppresses proliferation and collagen production but also increases collagenase activity of hepatic stellate cells (Fukushima et al..
· Inhibits endothelial cell migration, viability, and tube formation in vitro in HUVECs (Yin et al.)
· Improves adipocyte differentiation, preventing development of diabetes and nephropathy in insulin-resistant diabetic rats (Kikuchi et al.).

DISEASE MODELING
· Reduces pulmonary arterial hypertension in rats (Oka et al.).
· Enhances neurological recovery after traumatic spinal cord injury (Hara et al.).
· Inhibits corneal neovascularization after alkali burns and promotes the healing of corneal epithelial defects in mice (Zeng et al.).
Cell Type
Adipocytes, Endothelial Cells, HUVECs, Neural Stem and Progenitor Cells
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Differentiation
Area of Interest
Angiogenic Cell Research, Disease Modeling
CAS Number
203911-27-7
Chemical Formula
C₁₄H₁₇N₃O₂S · 2HCl
Purity
≥ 98%
Pathway
RHO/ROCK
Target
ROCK2

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
73662, 73664
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
73662, 73664
Lot #
All
Language
English

Resources and Publications

Publications (7)

Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in mice. Zeng P et al. Molecular vision 2015 JAN

Abstract

PURPOSE To investigate the effects and mechanisms of fasudil hydrochloride (fasudil) on and in alkali burn-induced corneal neovascularization (CNV) in mice. METHODS To observe the effect of fasudil, mice with alkali-burned corneas were treated with either fasudil eye drops or phosphate-buffered saline (PBS) four times per day for 14 consecutive days. After injury, CNV and corneal epithelial defects were measured. The production of reactive oxygen species (ROS) and heme oxygenase-1(HO-1) was measured. The infiltration of polymorphonuclear neutrophils (PMNs) and the mRNA expressions of CNV-related genes were analyzed on day 14. RESULTS The incidence of CNV was significantly lower after treatment with 100 μM and 300 μM fasudil than with PBS, especially with 100 μM fasudil. Meanwhile, the incidences of corneal epithelial defects was lower (n=15, all ptextless0.01). After treatment with 100 μM fasudil, the intensity of DHE fluorescence was reduced in the corneal epithelium and stroma than with PBS treatment (n=5, all ptextless0.01), and the number of filtrated PMNs decreased. There were significant differences between the expressions of VEGF, TNF-a, MMP-8, and MMP-9 in the 100 μM fasudil group and the PBS group (n=8, all ptextless0.05). The production of HO-1 protein in the 100 μM fasudil group was 1.52±0.34 times more than in the PBS group (n=5 sample, ptextless0.05). CONCLUSIONS 100 μM fasudil eye drops administered four times daily can significantly inhibit alkali burn-induced CNV and promote the healing of corneal epithelial defects in mice. These effects are attributed to a decrease in inflammatory cell infiltration, reduction of ROS, and upregulation of HO-1 protein after fasudil treatment.
Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Yin L et al. Molecular cancer therapeutics 2007 MAY

Abstract

Vascular endothelial growth factor (VEGF)-induced endothelial cell migration is an important component of tumor angiogenesis. Rho and Rho-associated kinase (ROCK) are key regulators of focal adhesion, stress fiber formation, and thus cell motility. Inhibitors of this pathway have been shown to inhibit endothelial cell motility and angiogenesis. In this study, we investigated the antiangiogenic effect of fasudil, one of the ROCK inhibitors. Fasudil inhibited VEGF-induced endothelial cell migration, viability, and tube formation in vitro in human umbilical vein endothelial cells. VEGF-induced endothelial cell migration was reduced by fasudil associated with loss of stress fiber formation, focal adhesion assembly, and with the suppression of tyrosine phosphorylation of focal adhesion proteins. Furthermore, fasudil inhibited VEGF-induced phosphorylation of myosin light chain, which is one of the main substrates of ROCK. Therefore, the effect of fasudil was suggested to be ROCK dependent. Fasudil not only inhibited VEGF-induced cell proliferation but also reversed the protective effect of VEGF on apoptosis, which resulted in the decrease of cell viability. Moreover, fasudil inhibited VEGF-induced angiogenesis in a directed in vivo angiogenesis assay. These data are the first demonstration that fasudil has antiangiogenic properties. Therefore, fasudil might be useful for the treatment of angiogenesis-related diseases, especially cancer.
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Oka M et al. Circulation research 2007 MAR

Abstract

Vascular remodeling, rather than vasoconstriction, is believed to account for high vascular resistance in severe pulmonary arterial hypertension (PAH). We have found previously that acute Rho kinase inhibition nearly normalizes PAH in chronically hypoxic rats that have no occlusive neointimal lesions. Here we examined whether Rho kinase-mediated vasoconstriction was also important in a rat model of severe occlusive PAH. Adult rats were exposed to chronic hypoxia ( approximately 10% O(2)) after subcutaneous injection of the vascular endothelial growth factor receptor inhibitor SUGEN 5416. Hemodynamic measurements were made in anesthetized rats after 2 weeks of hypoxia (early group) and 3 weeks of hypoxia plus 2 weeks of normoxia (late group). Both groups developed PAH, with greater severity in the late group. In the early group, intravenous fasudil was more effective than intravenous bradykinin, inhaled NO, or intravenous iloprost in reducing right ventricular systolic pressure. Despite more occlusive vascular lesions, fasudil also markedly reduced right ventricular systolic pressure in late-stage rats. Blood-perfused lungs from late-stage rats showed spontaneous vasoconstriction, which was reversed partially by the endothelin A receptor blocker BQ123 and completely by fasudil or Y-27632. Phosphorylation of MYPT1, a downstream target of Rho kinase, was increased in lungs from both groups of rats, and fasudil (intravenous) reversed the increased phosphorylation in the late group. Thus, in addition to structural occlusion, Rho kinase-mediated vasoconstriction is an important component of severe PAH in SUGEN 5416/hypoxia-exposed rats, and PAH can be significantly reduced in the setting of a severely remodeled lung circulation if an unconventional vasodilator is used.